Investigational drug · Phase 3
ABBV-444
Not approved by FDA. In 1 industry-sponsored Phase 2 or 3 trial that is active or finished in the last two years, most often for Dry Eye Disease.
Phase 3Last checked: Nov 19, 2026Latest source record: Sep 17, 2026 (newest trial update)Source: ClinicalTrials.govMethods & limitations
Highest phase
Phase 3
Industry-sponsored trials
Phase 2 and 3 trials
1
0 still active
All registered trials
2
Any phase or sponsor naming "ABBV-444"
First trial start
2025
Dec 15, 2025
Sponsors
Lead sponsors of its Phase 2 and 3 trials.
All registered trials by phase
Every ClinicalTrials.gov drug study naming "ABBV-444", any sponsor or status.
Conditions studied
As listed on its trial records.
- Dry Eye Disease
Approved drugs for the same conditions: Dry eye disease · Ophthalmology
Largest trials
Live from ClinicalTrials.gov: studies naming "ABBV-444" as an intervention, largest first.
- A Clinical Study to Evaluate the Effect and Side Effect of a New Artificial Tear Formulation (ABBV-444) Compared to Refresh Optive Unit Dose in Adult Participants With Dry Eye DiseasePivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT07284381 · 261 participants · Start Dec 15, 2025 · Primary completion Aug 21, 2026
Drug: ABBV-444; REFRESH OPTIVE UD · For: Dry Eye Disease
Sites: Dothan, Alabama; Chandler, Arizona; Azusa, California · 20 sites in all
- A Study to Assess Symptom Relief and Product Tolerability of ABBV-444 Drops in Adult ParticipantsPivotal-lookingCompleted
AbbVieAbbVie (ABBV)
NCT05878067 · 40 participants · Start Jun 27, 2023 · Primary completion Oct 6, 2023
Drug: ABBV-444 · For: Dry Eye Syndrome
Sites: Azusa, California
Newest research
PubMed records naming it or its code names, newest first.
- Patient Experience with ABBV-444, a Proof-of-Concept Study for a Novel Artificial Tear with Trehalose and Sodium Hyaluronate for Dry Eye Symptoms.
Hom MM, Ladhani O, Zhang Z, et al. · Clin Optom (Auckl) 2025
Also in development for Dry Eye Disease
Names are merged from how sponsors list this drug on ClinicalTrials.gov, so an alias can occasionally belong to a related compound. Development status changes faster than registry records do. More from AbbVie.
For information only. Nothing on this page is investment, legal, tax or medical advice, and nothing here is an offer to sell or a solicitation of an offer to buy any security. The data comes from public government sources, which can be incomplete, delayed or wrong. Check the original record before relying on it.